Pure Bioscience Files Q1 2025 10-Q

TL;DR

PURE 10-Q filed: Q1 FY25 results out. Check financials.

AI Summary

Pure Bioscience, Inc. filed a 10-Q for the period ending October 31, 2024. The company reported financial results for the first quarter of its fiscal year. Specific financial figures and operational details for this period are detailed within the filing.

Why It Matters

This filing provides investors with an update on Pure Bioscience's financial performance and operational status for the first quarter of fiscal year 2025.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information and risk factors that could impact the company's future performance.

Key Numbers

• 2024-10-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
• 2024-12-16 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• PURE BIOSCIENCE, INC. (company) — Filer of the 10-Q
• 2024-10-31 (date) — End of the reporting period
• 2024-12-16 (date) — Filing date
• 771 JAMACHA ROAD #512 (address) — Business and mailing address
• EL CAJON (city) — City of business and mailing address
• CA (state) — State of business and mailing address
• 92019 (zip_code) — ZIP code of business and mailing address
• 619-596-8600 (phone_number) — Business phone number

FAQ

Key Financial Figures

• $0.01 — ction 12(g) of the Act: Common Stock, $0.01 par value Indicate by check mark whet
• $0.095 — that such conversion price is at least $0.095 per share and less than or equal to $0.
• $0.175 — 095 per share and less than or equal to $0.175 per share, subject to certain customary

Filing Documents

• form10-q.htm (10-Q) — 474KB
• ex31-1.htm (EX-31.1) — 20KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 9KB
• ex32-2.htm (EX-32.2) — 9KB
• 0001493152-24-050227.txt ( ) — 2941KB
• pure-20241031.xsd (EX-101.SCH) — 22KB
• pure-20241031_cal.xml (EX-101.CAL) — 29KB
• pure-20241031_def.xml (EX-101.DEF) — 110KB
• pure-20241031_lab.xml (EX-101.LAB) — 211KB
• pure-20241031_pre.xml (EX-101.PRE) — 163KB
• form10-q_htm.xml (XML) — 319KB

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 14 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 21 Item 4.

Controls and Procedures

Controls and Procedures 21 PART II OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 22 Item 1A.

Risk Factors

Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23 Item 3. Defaults Upon Senior Securities 23 Item 4. Mine Safety Disclosures 23 Item 5. Other Information 23 Item 6. Exhibits 24

Signatures

Signatures 25 2 Part I - Financial Information Item 1. Financial Statements PURE Bioscience, Inc. Condensed Consolidated Balance Sheets October 31, 2024 July 31, 2024 (Unaudited) Assets Current assets Cash and cash equivalents $ 346,000 $ 349,000 Accounts receivable 371,000 298,000 Inventories, net 72,000 56,000 Restricted cash 75,000 75,000 Prepaid expenses 47,000 27,000 Total current assets 911,000 805,000 Property, plant and equipment, net 13,000 13,000 Total assets $ 924,000 $ 818,000 Liabilities and stockholders' deficiency Current liabilities Accounts payable $ 718,000 $ 601,000 Accrued liabilities 193,000 132,000 Total current liabilities 911,000 733,000 Long-term liabilities Convertible notes payable to related parties 3,509,000 2,949,000 Total long-term liabilities 3,509,000 2,949,000 Total liabilities 4,420,000 3,682,000 Commitments and contingencies - - Stockholders' deficiency Preferred stock, $ 0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding — — Common stock, $ 0.01 par value: 200,000,000 shares authorized, 111,856,473 shares issued and outstanding at October 31, 2024, and July 31, 2024 1,119,000 1,119,000 Additional paid-in capital 132,669,000 132,612,000 Accumulated deficit ( 137,284,000 ) ( 136,595,000 ) Total stockholders' deficiency ( 3,496,000 ) ( 2,864,000 ) Total liabilities and stockholders' deficiency $ 924,000 $ 818,000 See accompanying notes. 3 PURE Bioscience, Inc. Condensed Consolidated Statements of Operations (Unaudited) 2024 2023 Three months ended October 31, 2024 2023 Net product sales $ 555,000 $ 718,000 Royalty revenue 1,000 4,000 Total revenue 556,000 722,000 Cost of goods sold 231,000 280,000 Gross Profit 325,000 442,000 Operating costs and expenses Selling, general and administrative 881,000 1,073,000 Research and development 71,000 80,000

View Full Filing

View this 10-Q filing on SEC EDGAR